{"nctId":"NCT01760473","briefTitle":"Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone","startDateStruct":{"date":"2009-05"},"conditions":["Heroin Dependence"],"count":27,"armGroups":[{"label":"Bup 8","type":"EXPERIMENTAL","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Bup 16","type":"EXPERIMENTAL","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Bup/Nal 8/2","type":"EXPERIMENTAL","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Bup/Nal 8/8","type":"EXPERIMENTAL","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Bup/Nal 8/16","type":"EXPERIMENTAL","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Bup/Nal 16/4","type":"EXPERIMENTAL","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Heroin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Placebo","type":"SHAM_COMPARATOR","interventionNames":["Drug: Intranasal challenge drug"]},{"label":"Naloxone 4 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Intranasal challenge drug"]}],"interventions":[{"name":"Intranasal challenge drug","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* DSM IV criteria for heroin dependence\n* No major mood, psychotic, or anxiety disorder\n* Physically healthy\n* Able to perform study procedures\n* 21-45 years of age\n* Normal body weight\n* Current use of opioids in amounts and/or frequencies that meet or exceed those used in the proposed study (e.g., 1-2 bags of heroin per occasion at least twice per day)\n* Self-administer IN buprenorphine above placebo levels during the qualification phase (see below)\n\nExclusion Criteria:\n\n* DSM IV criteria for dependence on drugs other than opioids, nicotine or caffeine\n* Participants requesting treatment\n* Participants on parole or probation\n* Pregnancy or lactation\n* Birth, miscarriage or abortion within 6 months\n* Current or recent history of significant violent behavior\n* Current major Axis I psychopathology, other than opioid dependence (e.g., mood disorder with functional impairment or suicide risk, schizophrenia), that might interfere with ability to participate in the study\n* AST or ALT \\> 3 times the upper limit of normal\n* Significant suicide risk\n* Current chronic pain\n* Sensitivity, allergy, or contraindication to opioids\n* Current or recent (past 30 days) physical dependence on or treatment with methadone, buprenorphine, or the buprenorphine/naloxone combination","healthyVolunteers":true,"sex":"ALL","minimumAge":"21 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Drug Self-administration","description":"The maximum number of responses (clicks on a computer mouse) the participant was willing to perform in order to receive a dose of the intranasal challenge drug under investigation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":"135"},{"groupId":"OG001","value":"255","spread":"121"},{"groupId":"OG002","value":"223","spread":"113"},{"groupId":"OG003","value":"113","spread":"83"},{"groupId":"OG004","value":"2.7","spread":"2.7"},{"groupId":"OG005","value":"191","spread":"112"},{"groupId":"OG006","value":"755","spread":"156"},{"groupId":"OG007","value":"38","spread":"23"},{"groupId":"OG008","value":"45","spread":"30"}]}]}]},{"type":"SECONDARY","title":"SOWS","description":"Subjective opioid withdrawal scale (SOWS) measure (0-64). Greater score indicates more severe withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":".5"},{"groupId":"OG001","value":"3","spread":".7"},{"groupId":"OG002","value":"3","spread":".9"},{"groupId":"OG003","value":"3","spread":".8"},{"groupId":"OG004","value":"5","spread":"1"},{"groupId":"OG005","value":"3","spread":".5"},{"groupId":"OG006","value":"2","spread":".3"},{"groupId":"OG007","value":"2","spread":".53"},{"groupId":"OG008","value":"7","spread":"1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Elevated liver function test (AST/ALT)"]}}}